Kura Oncology, Inc. (KURA)

14.96 -0.58 (-3.73%) At close: 04:00PM EDT

Kura Oncology, Inc.

12730 High Bluff Drive
Suite 400
San Diego, CA 92130
United States
858 500 8800
https://kuraoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 123

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Troy Edward Wilson J.D., Ph.D.	Chairman, CEO, Pres & Principal Financial Officer	984.61k	N/A	1969
Ms. Kathleen Ford	Chief Operating Officer	689.32k	62.51k	1947
Dr. Marc Grasso M.D.	Advisor	651.68k	N/A	1974
Ms. Kirsten Flowers	Chief Commercial Officer	642.98k	N/A	1975
Dr. Stephen Dale M.D.	Chief Medical Officer	811.58k	N/A	1972
Mr. Thomas Doyle	Principal Accounting Officer & Sr. VP of Fin. and Accounting	N/A	N/A	1971
Mr. Pete De Spain	Sr. VP of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Teresa Brophy Bair Esq., J.D.	Chief Legal Officer & Corp. Sec.	N/A	N/A	1971
Mr. James E. Basta J.D., Esq.	Chief Compliance Officer & Corp. Sec.	N/A	N/A	1966
Dr. Roger Bakale Ph.D.	VP and Head of CMC, Clinical & Commercial Manufacturing	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Corporate governance

Kura Oncology, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.